Welcome to LookChem.com Sign In|Join Free

CAS

  • or

160777-08-2

Post Buying Request

160777-08-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

160777-08-2 Usage

Chemical Properties

White Solid

Uses

Precursor in the preparation of histone deacetylating agents

Check Digit Verification of cas no

The CAS Registry Mumber 160777-08-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,7,7 and 7 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 160777-08:
(8*1)+(7*6)+(6*0)+(5*7)+(4*7)+(3*7)+(2*0)+(1*8)=142
142 % 10 = 2
So 160777-08-2 is a valid CAS Registry Number.

160777-08-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 7-Oxo-7-(phenylamino)heptanoic Acid

1.2 Other means of identification

Product number -
Other names 7-Anilino-7-oxoheptanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:160777-08-2 SDS

160777-08-2Relevant articles and documents

Structural biasing elements for in-cell histone deacetylase paralog selectivity

Wong, Jason C.,Hong, Roger,Schreiber, Stuart L.

, p. 5586 - 5587 (2003)

We use the structural dissection of two 1,3-dioxanes with in-cell histone deacetylase (HDAC) paralog selectivity to identify key elements for selective HDAC inhibitors. We demonstrate that o-aminoanilides are inactive toward HDAC6 while apparently inhibit

HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES

-

Page/Page column 39, (2008/06/13)

The invention provides HDAC inhibitors that may be used as therapeutics for the treatment of a neurodegenerative or neuromuscular condition. The invention provides compounds of formula I. The invention also provides pharmaceutical compositions and articles of manufacture that include these compounds, as well as methods of treating and methods of preventing or delaying the onset of a neurodegenerative or neuromuscular condition.

Design and synthesis of non-hydroxamate histone deacetylase inhibitors: Identification of a selective histone acetylating agent

Suzuki, Takayoshi,Matsuura, Azusa,Kouketsu, Akiyasu,Hisakawa, Shinya,Nakagawa, Hidehiko,Miyata, Naoki

, p. 4332 - 4342 (2007/10/03)

A series of suberoylanilide hydroxamic acid (SAHA)-based non-hydroxamates was designed, synthesized, and evaluated for their histone deacetylase (HDAC) inhibitory activity. Among these, methyl sulfoxide 15 inhibited HDACs in enzyme assays and caused hyperacetylation of histone H4 while not inducing the accumulation of acetylated α-tubulin in HCT116 cells.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 160777-08-2